3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Unknown
1
Terminated
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Conditions
Prostatic Neoplasms
7
Polycystic Ovary Syndrome
5
Ovarian Hyperstimulation Syndrome
3
Infertility
3
Breast Neoplasms
2
The Neoadjuvant Therapy
1
Sarcoma, Ewing
1
Sarcoma
1
Osteosarcoma
1
Neoplasms
1
Neoadjuvant Therapy \ High Risk Prostate Cancer \ Docetaxel
1
Lymphoma
1
Helping Behavior
1
Interventions
Exercise
19
Drug Therapy
18
pembrolizumab
13
Capecitabine
11
Blood Specimen Collection
11
Surveys and Questionnaires
10
Radiotherapy
10
Paclitaxel
9
Dexamethasone
9
Nivolumab
8
Standard of Care
7
Oxaliplatin
7
Fluorouracil
7
Erlotinib Hydrochloride
7
apatinib
6
Interviews as Topic
6
Gemcitabine
6
Control Groups
6
Cisplatin
6
Therapeutics
5
Neoadjuvant Therapy
5
Mindfulness-Based Cognitive Therapy
5
Metformin
5
Injections
5
Everolimus
5
Docetaxel
5
Cyclophosphamide
5
Bevacizumab
5
sintilimab
4
atezolizumab
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Neoplasms
×
Triptorelin Pamoate
×
Clear all
NCT02856048
2019-12-17
PRESOV
Assistance Publique - Hôpitaux de Paris
Phase 2/3
Unknown
11 enrolled